{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T18:47:13Z","timestamp":1790794033807,"version":"4.1.0"},"reference-count":77,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2024,9,29]],"date-time":"2024-09-29T00:00:00Z","timestamp":1727568000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brain Sciences"],"abstract":"<jats:p>The landscape of pharmacological treatment for Alzheimer\u2019s disease (AD) has undergone significant transformations with the advent of disease-modifying therapies (DMTs) targeting \u03b2-Amyloid (A\u03b2) accumulation, one of the hallmark pathologies of AD. The approval and market introduction of monoclonal antibodies mark the dawn of a new era in AD therapeutics as well. Furthermore, considerable progress has also been made in the development of new drugs targeting non-A\u03b2 and non-Tau protein pathways. These advancements are key in tackling the root causes of AD, offering hope for treatments that both relieve symptoms and slow disease progression, improving patient outcomes and quality of life. This review aims to provide a comprehensive update on the advances in drug development and application for AD, including those currently in clinical trials and those already approved for the market to treat patients.<\/jats:p>","DOI":"10.3390\/brainsci14100990","type":"journal-article","created":{"date-parts":[[2024,9,30]],"date-time":"2024-09-30T08:09:52Z","timestamp":1727683792000},"page":"990","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Advancements in Pharmacological Treatment of Alzheimer\u2019s Disease: The Advent of Disease-Modifying Therapies (DMTs)"],"prefix":"10.3390","volume":"14","author":[{"given":"Qiong","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Critical Care Medicine, West China Hospital, Sichuan University, Chengdu 610041, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sihui","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Neurology, West China Hospital, Sichuan University, Chengdu 610041, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0892-9909","authenticated-orcid":false,"given":"Junhui","family":"Wang","sequence":"additional","affiliation":[{"name":"Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, ON M5G 1X5, Canada"},{"name":"Thyropathy Hospital, Sunsimiao Hospital, Beijing University of Chinese Medicine, Tongchuan 727000, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huifang","family":"Shang","sequence":"additional","affiliation":[{"name":"Department of Neurology, West China Hospital, Sichuan University, Chengdu 610041, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4290-7404","authenticated-orcid":false,"given":"Xueping","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Neurology, West China Hospital, Sichuan University, Chengdu 610041, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,9,29]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"595","DOI":"10.15252\/emmm.201606210","article-title":"The amyloid hypothesis of Alzheimer\u2019s disease at 25 years","volume":"8","author":"Selkoe","year":"2016","journal-title":"EMBO Mol. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1002\/ana.22615","article-title":"Pathogenic protein seeding in Alzheimer disease and other neurodegenerative disorders","volume":"70","author":"Jucker","year":"2011","journal-title":"Ann. Neurol."},{"key":"ref_3","first-page":"Cd001190","article-title":"Donepezil for dementia due to Alzheimer\u2019s disease","volume":"6","author":"Birks","year":"2018","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"108352","DOI":"10.1016\/j.neuropharm.2020.108352","article-title":"Efficacy of acetylcholinesterase inhibitors in Alzheimer\u2019s disease","volume":"190","author":"Marucci","year":"2021","journal-title":"Neuropharmacology"},{"key":"ref_5","first-page":"Cd001191","article-title":"Rivastigmine for Alzheimer\u2019s disease","volume":"4","author":"Birks","year":"2009","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1056\/NEJMoa013128","article-title":"Memantine in moderate-to-severe Alzheimer\u2019s disease","volume":"348","author":"Reisberg","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"964","DOI":"10.14336\/AD.2022.1127","article-title":"Gut Microbiota is an Impact Factor based on the Brain-Gut Axis to Alzheimer\u2019s Disease: A Systematic Review","volume":"14","author":"Zou","year":"2023","journal-title":"Aging Dis."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1007\/s12272-023-01463-0","article-title":"Review on pharmacological effects of gastrodin","volume":"46","author":"Xiao","year":"2023","journal-title":"Arch. Pharmacal. Res."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Cai, Y., Liu, J., Wang, B., Sun, M., and Yang, H. (2022). Microglia in the Neuroinflammatory Pathogenesis of Alzheimer\u2019s Disease and Related Therapeutic Targets. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.856376"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"7825","DOI":"10.2147\/IJN.S444115","article-title":"Current Anti-Amyloid-\u03b2 Therapy for Alzheimer\u2019s Disease Treatment: From Clinical Research to Nanomedicine","volume":"18","author":"Zhao","year":"2023","journal-title":"Int. J. Nanomed."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"247","DOI":"10.7861\/clinmedicine.16-3-247","article-title":"Drug treatments in Alzheimer\u2019s disease","volume":"16","author":"Briggs","year":"2016","journal-title":"Clin. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/S1474-4422(10)70119-8","article-title":"Alzheimer\u2019s disease: Clinical trials and drug development","volume":"9","author":"Mangialasche","year":"2010","journal-title":"Lancet Neurol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"eadk9993","DOI":"10.1126\/scitranslmed.adk9993","article-title":"Current status of amyloid-targeting immunotherapies for Alzheimer\u2019s disease","volume":"15","author":"Tabor","year":"2023","journal-title":"Sci. Transl. Med."},{"key":"ref_14","first-page":"211","article-title":"Detection and Management of Amyloid-Related Imaging Abnormalities in Patients with Alzheimer\u2019s Disease Treated with Anti-Amyloid Beta Therapy","volume":"9","author":"Barakos","year":"2022","journal-title":"J. Prev. Alzheimer\u2019s Dis."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.ejmech.2016.02.049","article-title":"Amyloid cascade in Alzheimer\u2019s disease: Recent advances in medicinal chemistry","volume":"113","author":"Mohamed","year":"2016","journal-title":"Eur. J. Med. Chem."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"685","DOI":"10.3233\/JAD-2012-120751","article-title":"\u03b3-Secretase modulator in Alzheimer\u2019s disease: Shifting the end","volume":"31","author":"Xia","year":"2012","journal-title":"J. Alzheimer\u2019s Dis."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1001\/archneurol.2012.2194","article-title":"Safety and tolerability of the \u03b3-secretase inhibitor avagacestat in a phase 2 study of mild to moderate Alzheimer disease","volume":"69","author":"Coric","year":"2012","journal-title":"Arch. Neurol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1523\/JNEUROSCI.3407-12.2013","article-title":"Enhanced proteolytic clearance of plasma A\u03b2 by peripherally administered neprilysin does not result in reduced levels of brain A\u03b2 in mice","volume":"33","author":"Walker","year":"2013","journal-title":"J. Neurosci."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"8797","DOI":"10.7150\/thno.61601","article-title":"Activating AhR alleviates cognitive deficits of Alzheimer\u2019s disease model mice by upregulating endogenous A\u03b2 catabolic enzyme Neprilysin","volume":"11","author":"Qian","year":"2021","journal-title":"Theranostics"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"4260","DOI":"10.1016\/j.cell.2023.08.021","article-title":"Alzheimer\u2019s disease: From immunotherapy to immunoprevention","volume":"186","author":"Jucker","year":"2023","journal-title":"Cell"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s40035-022-00292-3","article-title":"Immunotherapy for Alzheimer\u2019s disease: Targeting \u03b2-amyloid and beyond","volume":"11","author":"Song","year":"2022","journal-title":"Transl. Neurodegener."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1056\/NEJMoa1304839","article-title":"Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer\u2019s disease","volume":"370","author":"Salloway","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1056\/NEJMoa2304430","article-title":"Two Phase 3 Trials of Gantenerumab in Early Alzheimer\u2019s Disease","volume":"389","author":"Bateman","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1056\/NEJMoa2305032","article-title":"Trial of Solanezumab in Preclinical Alzheimer\u2019s Disease","volume":"389","author":"Sperling","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1001\/jamaneurol.2022.2909","article-title":"Evaluating the Safety and Efficacy of Crenezumab vs Placebo in Adults With Early Alzheimer Disease: Two Phase 3 Randomized Placebo-Controlled Trials","volume":"79","author":"Ostrowitzki","year":"2022","journal-title":"JAMA Neurol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s13311-022-01308-6","article-title":"Lecanemab, Aducanumab, and Gantenerumab\u2014Binding Profiles to Different Forms of Amyloid-Beta Might Explain Efficacy and Side Effects in Clinical Trials for Alzheimer\u2019s Disease","volume":"20","author":"Johannesson","year":"2023","journal-title":"Neurotherapeutics"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/nature19323","article-title":"The antibody aducanumab reduces A\u03b2 plaques in Alzheimer\u2019s disease","volume":"537","author":"Sevigny","year":"2016","journal-title":"Nature"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1001\/jamaneurol.2021.4161","article-title":"Amyloid-Related Imaging Abnormalities in 2 Phase 3 Studies Evaluating Aducanumab in Patients with Early Alzheimer Disease","volume":"79","author":"Salloway","year":"2022","journal-title":"JAMA Neurol."},{"key":"ref_29","first-page":"197","article-title":"Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer\u2019s Disease","volume":"9","author":"Aisen","year":"2022","journal-title":"J. Prev. Alzheimer\u2019s Dis."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2212948","article-title":"Lecanemab in Early Alzheimer\u2019s Disease","volume":"388","author":"Swanson","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_31","first-page":"771","article-title":"Lecanemab Clarity AD: Quality-of-Life Results from a Randomized, Double-Blind Phase 3 Trial in Early Alzheimer\u2019s Disease","volume":"10","author":"Cohen","year":"2023","journal-title":"J. Prev. Alzheimer\u2019s Dis."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s13195-021-00813-8","article-title":"A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer\u2019s disease with lecanemab, an anti-A\u03b2 protofibril antibody","volume":"13","author":"Swanson","year":"2021","journal-title":"Alzheimer\u2019s Res. Ther."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1186\/s13195-022-01124-2","article-title":"Lecanemab in patients with early Alzheimer\u2019s disease: Detailed results on biomarker, cognitive, and clinical effects from the randomized and open-label extension of the phase 2 proof-of-concept study","volume":"14","author":"McDade","year":"2022","journal-title":"Alzheimer\u2019s Res. Ther."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1126\/science.1078259","article-title":"Cerebral hemorrhage after passive anti-Abeta immunotherapy","volume":"298","author":"Pfeifer","year":"2002","journal-title":"Science"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa2100708","article-title":"Donanemab in Early Alzheimer\u2019s Disease","volume":"384","author":"Mintun","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1001\/jama.2023.13239","article-title":"Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial","volume":"330","author":"Sims","year":"2023","journal-title":"JAMA"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"102193","DOI":"10.1016\/j.arr.2024.102193","article-title":"Navigating the dementia landscape: Biomarkers and emerging therapies","volume":"94","author":"Maheshwari","year":"2024","journal-title":"Ageing Res. Rev."},{"key":"ref_38","first-page":"e074758","article-title":"Safety, tolerability, pharmacokinetics and pharmacodynamics of a single intravenous dose of SHR-1707 in healthy adult subjects: Two randomized, double-blind, phase 1 studies","volume":"19","author":"Hu","year":"2023","journal-title":"J. Alzheimer\u2019s Dis."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s40259-023-00633-2","article-title":"Anti-Amyloid Monoclonal Antibodies for the Treatment of Alzheimer\u2019s Disease","volume":"38","author":"Cummings","year":"2023","journal-title":"BioDrugs"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1056\/NEJMoa2308719","article-title":"Ultrasound Blood-Brain Barrier Opening and Aducanumab in Alzheimer\u2019s Disease","volume":"390","author":"Rezai","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Pardridge, W.M. (2020). Treatment of Alzheimer\u2019s Disease and Blood-Brain Barrier Drug Delivery. Pharmaceuticals, 13.","DOI":"10.3390\/ph13110394"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1001\/jamaneurol.2022.2793","article-title":"Association of Amyloid Reduction After Donanemab Treatment with Tau Pathology and Clinical Outcomes: The TRAILBLAZER-ALZ Randomized Clinical Trial","volume":"79","author":"Shcherbinin","year":"2022","journal-title":"JAMA Neurol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"562","DOI":"10.2214\/AJR.22.28461","article-title":"Amyloid-Related Imaging Abnormalities: An Update","volume":"220","author":"Roytman","year":"2023","journal-title":"AJR Am. J. Roentgenol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.3174\/ajnr.A3500","article-title":"MR imaging features of amyloid-related imaging abnormalities","volume":"34","author":"Barakos","year":"2013","journal-title":"AJNR Am. J. Neuroradiol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.ejmech.2017.07.070","article-title":"Tau protein aggregation in Alzheimer\u2019s disease: An attractive target for the development of novel therapeutic agents","volume":"139","author":"Jouanne","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1038\/s41591-023-02326-3","article-title":"Tau-targeting antisense oligonucleotide MAPT(Rx) in mild Alzheimer\u2019s disease: A phase 1b, randomized, placebo-controlled trial","volume":"29","author":"Mummery","year":"2023","journal-title":"Nat. Med."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Sinsky, J., Pichlerova, K., and Hanes, J. (2021). Tau Protein Interaction Partners and Their Roles in Alzheimer\u2019s Disease and Other Tauopathies. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22179207"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1152\/physrev.00024.2003","article-title":"Role of tau protein in both physiological and pathological conditions","volume":"84","author":"Avila","year":"2004","journal-title":"Physiol. Rev."},{"key":"ref_49","first-page":"780","article-title":"Oral Tau Aggregation Inhibitor for Alzheimer\u2019s Disease: Design, Progress and Basis for Selection of the 16 mg\/day Dose in a Phase 3, Randomized, Placebo-Controlled Trial of Hydromethylthionine Mesylate","volume":"9","author":"Wischik","year":"2022","journal-title":"J. Prev. Alzheimer\u2019s Dis."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1038\/s41591-023-02505-2","article-title":"Emerging diagnostics and therapeutics for Alzheimer disease","volume":"29","author":"Self","year":"2023","journal-title":"Nat. Med."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/j.vaccine.2006.09.046","article-title":"An update on smallpox vaccine candidates and their role in bioterrorism related vaccination strategies","volume":"25","author":"Wiser","year":"2007","journal-title":"Vaccine"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/s43587-021-00070-2","article-title":"ADAMANT: A placebo-controlled randomized phase 2 study of AADvac1, an active immunotherapy against pathological tau in Alzheimer\u2019s disease","volume":"1","author":"Novak","year":"2021","journal-title":"Nat. Aging"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.pharep.2015.07.006","article-title":"Therapeutic strategies for Alzheimer\u2019s disease in clinical trials","volume":"68","author":"Panek","year":"2016","journal-title":"Pharmacol. Rep."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1080\/13543784.2023.2233892","article-title":"Clinical development of passive tau-based immunotherapeutics for treating primary and secondary tauopathies","volume":"32","author":"Panza","year":"2023","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1038\/s41582-023-00883-2","article-title":"Tau-targeting therapies for Alzheimer disease: Current status and future directions","volume":"19","author":"Congdon","year":"2023","journal-title":"Nat. Rev. Neurol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s40478-020-0884-2","article-title":"Pre-clinical characterisation of E2814, a high-affinity antibody targeting the microtubule-binding repeat domain of tau for passive immunotherapy in Alzheimer\u2019s disease","volume":"8","author":"Roberts","year":"2020","journal-title":"Acta Neuropathol. Commun."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1038\/s41586-023-06788-w","article-title":"Disease-specific tau filaments assemble via polymorphic intermediates","volume":"625","author":"Li","year":"2024","journal-title":"Nature"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/nrn.2015.1","article-title":"Tau in physiology and pathology","volume":"17","author":"Wang","year":"2016","journal-title":"Nat. Rev. Neurosci."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1016\/S0140-6736(22)02480-1","article-title":"Lecanemab for Alzheimer\u2019s disease: Tempering hype and hope","volume":"400","author":"The","year":"2022","journal-title":"Lancet"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/S1474-4422(22)00529-4","article-title":"Lecanemab slows Alzheimer\u2019s disease: Hope and challenges","volume":"22","author":"Mead","year":"2023","journal-title":"Lancet Neurol."},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Twarowski, B., and Herbet, M. (2023). Inflammatory Processes in Alzheimer\u2019s Disease-Pathomechanism, Diagnosis and Treatment: A Review. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24076518"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"289","DOI":"10.2217\/nmt-2021-0022","article-title":"NM101 Phase III study of NE3107 in Alzheimer\u2019s disease: Rationale, design and therapeutic modulation of neuroinflammation and insulin resistance","volume":"11","author":"Reading","year":"2021","journal-title":"Neurodegener. Dis. Manag."},{"key":"ref_63","first-page":"Cd003154","article-title":"Memantine for dementia","volume":"3","author":"McShane","year":"2019","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"263","DOI":"10.2217\/nmt-2021-0019","article-title":"Masitinib for the treatment of Alzheimer\u2019s disease","volume":"11","author":"Ettcheto","year":"2021","journal-title":"Neurodegener. Dis. Manag."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s13195-023-01169-x","article-title":"Masitinib for mild-to-moderate Alzheimer\u2019s disease: Results from a randomized, placebo-controlled, phase 3, clinical trial","volume":"15","author":"Dubois","year":"2023","journal-title":"Alzheimer\u2019s Res. Ther."},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Wang, H.Y., Cecon, E., Dam, J., Pei, Z., Jockers, R., and Burns, L.H. (2023). Simufilam Reverses Aberrant Receptor Interactions of Filamin A in Alzheimer\u2019s Disease. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms241813927"},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"Wang, H.Y., Pei, Z., Lee, K.C., Nikolov, B., Doehner, T., Puente, J., Friedmann, N., and Burns, L.H. (2023). Simufilam suppresses overactive mTOR and restores its sensitivity to insulin in Alzheimer\u2019s disease patient lymphocytes. Front. Aging, 4.","DOI":"10.3389\/fragi.2023.1175601"},{"key":"ref_68","first-page":"e082892","article-title":"Protective Effects of AR1001 in Alzheimer\u2019s Disease Models: Polypharmacological Mechanisms","volume":"19","author":"Kang","year":"2023","journal-title":"J. Alzheimer\u2019s Dis."},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Ryskamp, D.A., Korban, S., Zhemkov, V., Kraskovskaya, N., and Bezprozvanny, I. (2019). Neuronal Sigma-1 Receptors: Signaling Functions and Protective Roles in Neurodegenerative Diseases. Front. Neurosci., 13.","DOI":"10.3389\/fnins.2019.00862"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"6742","DOI":"10.1073\/pnas.1422001112","article-title":"Sigma-1 receptor regulates Tau phosphorylation and axon extension by shaping p35 turnover via myristic acid","volume":"112","author":"Tsai","year":"2015","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Christ, M.G., Huesmann, H., Nagel, H., Kern, A., and Behl, C. (2019). Sigma-1 Receptor Activation Induces Autophagy and Increases Proteostasis Capacity In Vitro and In Vivo. Cells, 8.","DOI":"10.3390\/cells8030211"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1007\/978-3-030-12457-1_28","article-title":"At the Crossing of ER Stress and MAMs: A Key Role of Sigma-1 Receptor?","volume":"1131","author":"Delprat","year":"2020","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1016\/j.bbamem.2016.03.018","article-title":"On the physiological\/pathological link between A\u03b2 peptide, cholesterol, calcium ions and membrane deformation: A molecular dynamics study","volume":"1858","author":"Pannuzzo","year":"2016","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_74","doi-asserted-by":"crossref","unstructured":"Hampel, H., Caraci, F., Cuello, A.C., Caruso, G., Nistic\u00f2, R., Corbo, M., Baldacci, F., Toschi, N., Garaci, F., and Chiesa, P.A. (2020). A Path Toward Precision Medicine for Neuroinflammatory Mechanisms in Alzheimer\u2019s Disease. Front. Immunol., 11.","DOI":"10.3389\/fimmu.2020.00456"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.neurobiolaging.2023.09.010","article-title":"Early treatment with an M1 and sigma-1 receptor agonist prevents cognitive decline in a transgenic rat model displaying Alzheimer-like amyloid pathology","volume":"132","author":"Orciani","year":"2023","journal-title":"Neurobiol. Aging"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.trci.2018.11.001","article-title":"A phase 1 clinical trial of the sigma-2 receptor complex allosteric antagonist CT1812, a novel therapeutic candidate for Alzheimer\u2019s disease","volume":"5","author":"Grundman","year":"2019","journal-title":"Alzheimer\u2019s Dement."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s40035-023-00358-w","article-title":"A phase 1b randomized clinical trial of CT1812 to measure A\u03b2 oligomer displacement in Alzheimer\u2019s disease using an indwelling CSF catheter","volume":"12","author":"LaBarbera","year":"2023","journal-title":"Transl. Neurodegener."}],"container-title":["Brain Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-3425\/14\/10\/990\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:06:25Z","timestamp":1760112385000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-3425\/14\/10\/990"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,29]]},"references-count":77,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2024,10]]}},"alternative-id":["brainsci14100990"],"URL":"https:\/\/doi.org\/10.3390\/brainsci14100990","relation":{},"ISSN":["2076-3425"],"issn-type":[{"value":"2076-3425","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,29]]}}}